Search Results - "Hauser SL"

Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Authors: Kappos L Li D Calabresi PA et al.

Source: Lancet. 11/19/2011, Vol. 378 Issue 9805, p1779-1787. 9p.

B-cell depletion with rituximab in relapsing-remitting multiple sclerosis.

Authors: Hauser SL Waubant E Arnold DL et al.

Source: New England Journal of Medicine. 2/14/2008, Vol. 358 Issue 7, p676-688. 13p.

URL: 29418983

Global clinical trials: Challenges ahead.

Authors: Hauser SL Johnston SC

Source: Annals of Neurology. 2011 Oct, Vol. 70 Issue 4, pA8-9. 1p.

Personalized genetic scans: with gifts like these.

Authors: Hauser SL Johnston SC

Source: Annals of Neurology. Mar2009, Vol. 65 Issue 3, pA7-9. 1p.

Medical prizes: lifetime achievement awards or engines for progress?

Authors: Johnston SC Hauser SL

Source: Annals of Neurology. May2007, Vol. 61 Issue 5, pA11-2. 1p.

Marketing and drug costs: who is laughing and crying?

Authors: Johnston SC Hauser SL

Source: Annals of Neurology. Feb2007, Vol. 61 Issue 2, pA11-2. 1p.

Copy number variation in pediatric multiple sclerosis.

Authors: McElroy, JP Krupp, LB Johnson, BA et al.

Source: Multiple Sclerosis Journal. Jul2013, Vol. 19 Issue 8, p1014-1021. 8p. 2 Color Photographs, 1 Diagram, 1 Chart, 2 Graphs.

Rituximab in relapsing-remitting multiple sclerosis.

Authors: Schrijver HM De Palma R Sementa A et al.

Source: New England Journal of Medicine. 6/12/2008, Vol. 358 Issue 24, p2645-2647. 3p.

URL: 32574780

Genomewide study of multiple sclerosis.

Authors: Ramagopalan SV Anderson C Sadovnick AD et al.

Source: New England Journal of Medicine. 11/22/2007, Vol. 357 Issue 21, p2199-2201. 3p.

URL: 27558401

Early editorial manuscript screening versus obligate peer review: a randomized trial.

Authors: Johnston SC Lowenstein DH Ferriero DM et al.

Source: Annals of Neurology. Apr2007, Vol. 61 Issue 4, pA10-2. 1p.

Clinical validation of a novel in vitro diagnostic neurofilament light chain assay for the prognostication of disease activity in people with relapsing multiple sclerosis.

Authors: Ziemssen T Freedman MS Bar-Or A et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Nov; Vol. 31 (13), pp. 1543-1556. Date of Electronic Publication: 2025 Oct 29.

Publication Type: Journal Article; Validation Study

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Investigating the impact of age on neurodegeneration after optic neuritis in multiple sclerosis using optical coherence tomography.

Authors: Reinsberg HK Oertel FC Casillas D et al.

Corporate Authors: Reinsberg HK Oertel FC Casillas D et al.

Source: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2025 Oct; Vol. 31 (12), pp. 1493-1505. Date of Electronic Publication: 2025 Oct 21.

Publication Type: Journal Article

Journal Info: Publisher: SAGE Publications Country of Publication: England NLM ID: 9509185 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1477-0970 (Electronic) Linking ISSN: 13524585 NLM ISO Abbreviation: Mult Scler Subsets: MEDLINE

Reply to "Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence".

Authors: Cerono G Cree BAC Hauser SL et al.

Source: Annals of neurology [Ann Neurol] 2026 Jun; Vol. 99 (6), pp. 1614-1615. Date of Electronic Publication: 2026 Apr 07.

Publication Type: Letter

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE; In Process

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials.

Authors: Hauser SL Giovannoni G Montalban X et al.

Corporate Authors: Hauser SL Giovannoni G Montalban X et al.

Source: Lancet (London, England) [Lancet] 2026 May 30; Vol. 407 (10544), pp. 2180-2194.

Publication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Clinical Trial, Phase III

Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

Development of a Diagnostic Autoantibody Assay to a Consensus Motif for the Risk Prediction of Epstein-Barr Virus-Related Multiple Sclerosis.

Authors: McCutcheon KM Bodansky A Ngo TT et al.

Corporate Authors: McCutcheon KM Bodansky A Ngo TT et al.

Source: Neurology(R) neuroimmunology & neuroinflammation [Neurol Neuroimmunol Neuroinflamm] 2026 May; Vol. 13 (3), pp. e200551. Date of Electronic Publication: 2026 Mar 13.

Publication Type: Journal Article

Journal Info: Publisher: Wolters Kluwer Health/Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 101636388 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2332-7812 (Electronic) Linking ISSN: 23327812 NLM ISO Abbreviation: Neurol Neuroimmunol Neuroinflamm Subsets: MEDLINE

An optimized MP2RAGE protocol for spinal cord imaging in multiple sclerosis.

Authors: Papinutto N Stern WA Sacco S et al.

Source: AJNR. American journal of neuroradiology [AJNR Am J Neuroradiol] 2026 Mar 26. Date of Electronic Publication: 2026 Mar 26.

Publication Type: Journal Article

Journal Info: Publisher: American Society of Neuroradiology Country of Publication: United States NLM ID: 8003708 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1936-959X (Electronic) Linking ISSN: 01956108 NLM ISO Abbreviation: AJNR Am J Neuroradiol Subsets: MEDLINE

Antigen specificity of clonally enriched CD8⁺ T cells in multiple sclerosis.

Authors: Hayashi F Mittl K Dandekar R et al.

Corporate Authors: Hayashi F Mittl K Dandekar R et al.

Source: Nature immunology [Nat Immunol] 2026 Mar; Vol. 27 (3), pp. 490-502. Date of Electronic Publication: 2026 Feb 05.

Publication Type: Journal Article

Journal Info: Publisher: Nature America Inc Country of Publication: United States NLM ID: 100941354 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2916 (Electronic) Linking ISSN: 15292908 NLM ISO Abbreviation: Nat Immunol Subsets: MEDLINE

Reply to "New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond".

Authors: Sabatino JJ Jr Cree BAC Hauser SL

Source: Annals of neurology [Ann Neurol] 2026 Feb; Vol. 99 (2), pp. 549-550. Date of Electronic Publication: 2025 Dec 24.

Publication Type: Letter

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE; In Process

Comparative Safety Profiles of Ocrelizumab and Rituximab in Multiple Sclerosis Treatment Using Real-World Evidence.

Authors: Cerono G Cree BAC Hauser SL et al.

Source: Annals of neurology [Ann Neurol] 2026 Jan; Vol. 99 (1), pp. 248-260. Date of Electronic Publication: 2025 Sep 08.

Publication Type: Journal Article; Comparative Study

Journal Info: Publisher: Wiley-Liss Country of Publication: United States NLM ID: 7707449 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1531-8249 (Electronic) Linking ISSN: 03645134 NLM ISO Abbreviation: Ann Neurol Subsets: MEDLINE

Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis.

Authors: Hauser SL Freedman MS Nakahara J et al.

Source: Multiple sclerosis and related disorders [Mult Scler Relat Disord] 2026 Jan; Vol. 105, pp. 106886. Date of Electronic Publication: 2025 Nov 25.

Publication Type: Clinical Trial, Phase III; Journal Article

Journal Info: Publisher: Elsevier B. V Country of Publication: Netherlands NLM ID: 101580247 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2211-0356 (Electronic) Linking ISSN: 22110348 NLM ISO Abbreviation: Mult Scler Relat Disord Subsets: MEDLINE